



OPEN ACCESS

EDITED BY

Vivek Sharma,
Birla Institute of Technology and
Science, India

REVIEWED BY

Ashish Misra,
Indian Institute of Technology
Hyderabad, India
Christos K. Kontos,
National and Kapodistrian University of
Athens, Greece

*CORRESPONDENCE

Leonard Lipovich,
leonard.lipovich@mbru.ac.ae
Félix Fernandez-Madrid,
aa1108@wayne.edu

[†]These authors have contributed equally
to this work

SPECIALTY SECTION

This article was submitted to RNA,
a section of the journal
Frontiers in Genetics

RECEIVED 16 June 2022

ACCEPTED 15 November 2022

PUBLISHED 29 March 2023

CITATION

Obaidat D, Giordo R, Kleinbrink EL,
Banisad E, Grossman LI, Arshad R,
Stark A, Maroun M-C, Lipovich L and
Fernandez-Madrid F (2023), Non-
coding regions of nuclear-DNA-
encoded mitochondrial genes and
intergenic sequences are targeted by
autoantibodies in breast cancer.
Front. Genet. 13:970619.
doi: 10.3389/fgene.2022.970619

COPYRIGHT

© 2023 Obaidat, Giordo, Kleinbrink,
Banisad, Grossman, Arshad, Stark,
Maroun, Lipovich and Fernandez-
Madrid. This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Non-coding regions of nuclear-DNA-encoded mitochondrial genes and intergenic sequences are targeted by autoantibodies in breast cancer

Deya Obaidat¹, Roberta Giordo^{2†}, Erica L. Kleinbrink^{3,4†},
Emilia Banisad¹, Lawrence I. Grossman³, Rooshan Arshad³,
Azadeh Stark⁵, Marie-Claire Maroun¹, Leonard Lipovich^{2,6*} and
Félix Fernandez-Madrid^{1,3,7*}

¹Department of Internal Medicine, Division of Rheumatology, Wayne State University School of Medicine, Detroit, MI, United States, ²Department of Basic Medical Sciences, College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates, ³Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, United States, ⁴Quantitative Life Sciences, McGill University, Montreal, QC, Canada, ⁵Department of Pathology, Henry Ford Health System, Detroit, MI, United States, ⁶Shenzhen Huayuan Biotechnology Co. Ltd, Shenzhen Huayuan Biological Science Research Institute, Shenzhen, Guangdong, China, ⁷Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States

Autoantibodies against mitochondrial-derived antigens play a key role in chronic tissue inflammation in autoimmune disorders and cancers. Here, we identify autoreactive nuclear genomic DNA (nDNA)-encoded mitochondrial gene products (*GAPDH*, *PKM2*, *GSTP1*, *SPATA5*, *MFF*, *TSPOAP1*, *PHB2*, *COA4*, and *HAGH*) recognized by breast cancer (BC) patients' sera as nonself, supporting a direct relationship of mitochondrial autoimmunity to breast carcinogenesis. Autoreactivity of multiple nDNA-encoded mitochondrial gene products was mapped to protein-coding regions, 3' untranslated regions (UTRs), as well as introns. In addition, autoantibodies in BC sera targeted intergenic sequences that may be parts of long non-coding RNA (lncRNA) genes, including *LINC02381* and other putative lncRNA neighbors of the protein-coding genes *ERCC4*, *CXCL13*, *SOX3*, *PCDH1*, *EDDM3B*, and *GRB2*. Increasing evidence indicates that lncRNAs play a key role in carcinogenesis. Consistent with this, our findings suggest that lncRNAs, as well as mRNAs of nDNA-encoded mitochondrial genes, mechanistically contribute to BC progression. This work supports a new paradigm of breast carcinogenesis based on a globally dysfunctional genome with altered function of multiple mitochondrial and non-mitochondrial oncogenic pathways caused by the effects of autoreactivity-induced dysregulation of multiple genes and their products. This autoimmunity-based model of carcinogenesis will open novel avenues for BC treatment.

KEYWORDS

breast cancer, mitochondria, autoimmunity, long non-coding RNA, carcinogenesis, phage display

Introduction

A comprehensive immunofluorescence (IFA) survey of autoantibodies in women with pathology-verified BC and benign breast disease (BBD) detected the presence of high-titer autoantibodies consistently targeting mitochondria, centrosomes, centromeres, and other organelles as well as subcellular structures (Fernández Madrid et al., 2015). These autoantibodies were also detected in the sera of a small group of healthy women with suspicious mammography assessment and BBD, suggesting that the process triggering autoantibody formation begins in the pre-malignant phase (Fernández Madrid et al., 2015) or occurs—to some extent—in the absence of malignancy. This study supports our proposal that the autoantibody profile in BC, similarly to the accepted role of autoantibodies in the pathogenesis of rheumatic autoimmune diseases (RADs) (Tan, 1982; Suurmond and Diamond, 2015), mechanistically participates in the process of carcinogenesis. Until the report that anti-mitochondrial antibodies (AMAs) are found consistently in BC sera (Fernández Madrid et al., 2015), only two diseases, primary biliary cholangitis (PBC) and pemphigus vulgaris (PV), were known to consistently exhibit AMAs in sera (Gershwin et al., 1987; Fritzler and Manns, 2002; Marchenko et al., 2010). The role of mitochondrial autoimmunity in carcinogenesis (Fernández Madrid et al., 2015) is further supported by the report that key enzyme components of the mitochondrial electron transport chain (ETC) are BC autoantigens (Maroun et al., 2017), and more recently by the demonstration that autoimmunity is responsible for the direct participation of MNRR1 in breast carcinogenesis (Aras et al., 2019). These foundational studies suggested that a comprehensive survey of mitochondrial autoreactivity in BC would provide insight into the process of carcinogenesis.

The post-genomic era has enhanced our understanding of transcriptional and post-transcriptional events, including gene regulatory processes. In addition to the canonical protein-encoding open reading frames (ORFs) of protein-coding genes, long non-coding RNAs (lncRNAs) are increasingly recognized as important players in gene regulation (Kung et al., 2013), and they occasionally encode novel short peptides translated from their internal small ORFs (smORFs) (Dragomir et al., 2020). Additionally, large numbers of short non-canonical ORFs have been discovered in the 5'-UTRs (upstream ORFs (uORFs)) and 3'-UTRs (downstream ORFs (dORFs)) of protein-coding genes (Barbosa et al., 2013), and it is reasonable to posit that peptides translated from lncRNA smORFs as well as from mRNA uORFs and dORFs may be antigenic. Although uORFs appear to regulate gene expression, often repressing the downstream canonical ORF of the gene's known protein product, the function of dORFs remains unclear. A recent report suggested a translational stimulatory

function of dORFs in eukaryotic genes (Wu et al., 2020). In the present study, we report the discovery and initial functional characterization of a group of autoreactive nDNA-encoded mitochondrial gene products revealed by immune-screening two complementary-DNA (cDNA) libraries, followed by microarray analyses of potential BC autoantigens that reflect the participation of mitochondrial autoimmunity in breast carcinogenesis. As evidence of the complexity of carcinogenesis, we also report a group of non-mitochondrial autoreactive lncRNAs, which may mechanistically contribute to BC progression.

Materials and methods

Patient cohort and sampling

From a cohort of women ≥ 40 years of age undergoing annual screening mammography with Breast Imaging Reporting and Data System 4 (BI-RADS4) assessment at the Henry Ford Health System (HFHS), Detroit, Michigan, United States, we selected sera from 100 women who were diagnosed with infiltrating ductal carcinoma (IDC) by pathologic exam (the sera were obtained prior to any treatment). The demographics of the study group were 60% White Americans (including of Hispanic heritage), 30% African Americans and 10% Asian Americans, Native Americans, Native Alaskan and mixed-race. Sera used as controls were obtained from 100 healthy women, selected out of the same patient population, with biopsy-proven BBD and no cancer. The demographic characteristics of these cases and controls have been previously reported (Fernández Madrid et al., 2015). Each of these women was invited to donate a 10 ml blood sample after signing an informed consent. The study was approved by the HFHS and the Wayne State University IRBs.

Construction of complementary-DNA expression libraries

The construction and immune-screening of cDNA expression libraries, the assembly of micro-collections of the cloned phages on derivatized glass slides, the identification of unique clones, the cDNA sequence determination, and the homology searches of informative phages in databases have all been reported (Fernández Madrid et al., 2004; Maroun et al., 2017; Aras et al., 2019), and were adapted to identify the autoreactome in BC with emphasis on the mitochondria. Because immunoglobulins could paradoxically be expressed in epithelial cancer cells, and contribute to immunoglobulin synthesis, and perhaps to antigen presentation (Cui et al., 2021), we utilized two different human cDNA expression

libraries to characterize the BC autoreactome: a random-primed library established BC cell lines, and a tumor tissue-derived cDNA library of commercial origin (Novagen) that we used in our previous work (Fernández Madrid et al., 2004). Our goal was to identify the source of the potential BC antigens, and to ascertain which autoantigens are generated specifically within epithelial cancer cells, without the direct contribution of any other cells present in the tumor microenvironment such as antigen-presenting cells (multi-cell line library), and those which are generated in the patient tumor tissues (tumor tissue-derived library, Novagen). The known heterogeneity of BC (Miller et al., 1988) was an additional factor in support of including the multi-BC-cell-line cDNA library. Since the inherent heterogeneity of BC in the multi-cell line library likely exceeds that in the patient-derived library, we expected to detect signals in the cell line library that are not present in the patient derived library. The multi-cell-line library was constructed by directional cloning of randomly primed cDNA from 7 human breast carcinoma cell lines (SUM 44, SUM 102, SUM 149, SUM 159, MCF7, SKBR, T47D), and a pre-malignant cell line (MCF10A), into a T7 phage display vector, using the T7 Select 10-3b vector and the Orient Express cDNA library construction system (Novagen, Billerica, MA, United States), as reported (Maroun et al., 2017). Further information about culture of BC cells and RNA extraction and purification of the multi BC cell line cDNA library construction can be found in [Supplementary Material](#). Having a multi-cell line library in this study represents the heterogeneity of breast cancer and provides wider diversity of potential antigens than cDNA libraries of commercial origin that utilize RNA from a single case of BC. This cDNA library is novel and to our knowledge has not been reported before.

Selection of anti-mitochondrial antibodies-enriched breast cancer sera for immune-screening complementary-DNA libraries

The approach used to facilitate the identification of potential mitochondrial autoantigens consisted of using BC sera containing high-titer AMAs ($\geq 1:320$ – 640 dilution), detected by IFA on human Epithelial type 2 (HEp-2) cells, as biopanning sera. A/G agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA), incubated overnight with $100\ \mu\text{l}$ of a 1:50 dilution of cloning sera at 4°C , were used to react with a culture of *Escherichia coli* strain BLT5403, which was then lysed and centrifuged. Up to 5 rounds of biopanning were performed on the resulting supernatant as we described. The initial rounds did not yield individual unique phages but a mixture of phages with different inserts. Hence, biopanning was repeated until lysed clones yielded unique phages, as indicated by single DNA bands by PCR.

Autoantigen microarray development

A microarray was constructed in triplicate on fluorescent array surface technology glass slides using a Flexys robot (Genomic Systems) as reported (Fernández Madrid et al., 2004; Maroun et al., 2017; Aras et al., 2019). Briefly, plaque-pure phages, which had a single band by PCR, were grown to high titer in bacterial cultures that were incubated until complete lysis. Supernatants were collected after a 10 min, $10,000 \times g$ spin and then were arrayed in 384-well microtiter dishes. Each slide printed with phage clones was hybridized either with an individual serum from the collection of patients with IDC of the breast or with a non-cancer control serum. Slides were then treated with a mouse monoclonal antibody against the non-variable T7 phage coat protein (Novagen). CY3-labeled anti-human secondary antibodies and CY5-labeled anti-mouse antibodies were used to assess patient autoreactivity and to quantify phage concentration as reported (Fernández Madrid et al., 2004). The insert size of individual clones of the complete library was analyzed by PCR as reported (Fernández Madrid et al., 2004). Biopanning with BC sera containing high-titer AMAs was followed by microarray assembly of the whole collection of identified clones, hybridization of the potential BC autoantigens with sera from cases and non-cancer controls with exclusion of sera used for biopanning, and development of the autoantigen microarray as reported (Maroun et al., 2017). Briefly, the array background intensity was subtracted from the foreground intensity. Negative values were replaced by a value equal to half the minimum positive value. The within-array median normalization was used on the \log_2 ratios of red and green intensities. Replicated spots for the same marker were then summarized using median intensities. The statistical significance of the reactivity of the AMAs with BC diagnosis was determined individually as reported (Aras et al., 2019). Student's *t*-test was used for identifying the markers that differentiate IDC from the control group. PCR, sequence analyses, homology searches, hybridization of the printed phages on glass slides, and development of the autoantigen microarray and data pre-processing were performed as previously described (Fernández Madrid et al., 2004; Maroun et al., 2017).

Sequence analysis and bioinformatics


After identifying informative phages, the corresponding cDNA inserts were amplified by PCR with primers flanking the insertion site and sequenced commercially using Sanger sequencing (Genewiz, South Plainfield, NJ). The sequences deduced from the cloned cDNA were searched for vector contamination with the NCBI VecScreen tool, and the vector-containing clones were eliminated. The remaining sequences were screened by RepeatMasker (www.RepeatMasker.org) to detect repetitive sequences. The GenBank database was

searched for sequence homology to the identified cDNA sequences using the Basic Local Alignment Search Tool (BLAST) program (Altschul et al., 1994). When BLASTn showed highly significant homology, usually in the range of 98%–100% identity, to a sequence other than a protein-coding exon, we analyzed the sequence by the UCSC Genome Browser's BLAST-like alignment tool (BLAT). The ORF-encoded proteins and the intergenic-mapping phage sequences significantly recognized by BC sera on the microarray, but not by control sera, were analyzed by BLAT. We searched for the closest coding gene to these sequences; if the closest gene was a lncRNA sequence we also searched for the closest protein-coding gene within 500 kb distance because of the well-established knowledge that non-coding RNA genes can regulate the function and expression of their neighboring protein-coding genes (Katayama et al., 2005). Homologies detected by BLASTn or BLASTx were used, the smallest E-values were recorded, and conserved domains in the query sequences were determined. All the results from homology searches were genomically mapped by the BLAT functionality of the UCSC Genome Browser (Kent et al., 2002). We used the UCSC Genome Browser (Kent et al., 2002) to manually annotate the genomic mapping locations of all autoreactive phage sequences. We used the hg19 human genome assembly (except for the phage sequence of the non-coding neighbor of *EDDM3B*, which fails to map by BLAT to hg19 and only BLAT-maps to hg38) (Supplementary Material), incorporating all pertinent browser tracks including but not limited to mRNAs, ESTs, evolutionary conservation, RNA-seq, ENCODE Consortium epigenetics data, and reference gene models from NCBI RefSeq and the Gencode human gene catalog, into the analysis. The gene ontology (GO) analysis for the whole collection of potential breast autoantigens has been partially reported (Maroun et al., 2017). BLAST and BLAT (Altschul et al., 1994; Kent et al., 2002) output from the autoantigen microarray analysis was used to generate a gene list utilized as input for GO analysis using R. The R package Biomart is a collection of databases implementing the Biomart software suite (<http://www.biomart.org>). It facilitates the retrieval of large amounts of data with a simple query (Bio-Conductor version: Release 3.2). The analysis created a text file of GO identifiers corresponding to the BLAST/BLAT input gene list.


Results

Nuclear genomic DNA-encoded mitochondrial gene products are targeted by autoantibodies in breast cancer sera

From the 868 phage sequences that immunoreacted with BC sera during immune-screening of cDNA libraries, 547 showing single bands by PCR were successfully mapped to known human genes. Of these, 184 were unique sequences significantly associated with the diagnosis of invasive BC by autoantigen microarray analyses. Although 87 of these sequences were




encoded by mitochondrial DNA (mtDNA) (Maroun et al., 2017), 97 were encoded by nDNA, including those mapping to twelve mitochondrial genes (Figure 1): glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*), pyruvate kinase isoenzyme M2 (*PKM2*), glutathione S-transferase Pi 1 (*GSTP1*) (Figure 2), spermatogenesis-associated protein 5 (*SPATA5*), mitogen activated protein kinase 3 (*MAPK3*), cytochrome c oxidase polypeptide 7A2 (*COX7A2*) (Figure 3), mitochondrial fission factor (*MFF*), peripheral-type benzodiazepine receptor-associated protein 1 (*TSP0AP1*), prohibitin 2 (*PHB2*) (Figure 4), cytochrome C oxidase assembly factor 4 homolog (*COA4*), hydroxyacylglutathione hydrolase (*HAGH*), and mitochondrial nuclear retrograde regulator 1 (*MNRR1*) (Figure 5), also called *CHCHD2*, and highlighted in our prior work as an autoreactive mitochondrial gene in BC (Aras et al., 2019) (Table 1; Supplementary Material). From the nDNA-encoded mitochondrial gene products listed in Table 1, ten were cloned from the multi-human BC cell line cDNA library and



two from the BC tumor tissue-derived library (Novagen). **GAPDH** and **GSTP1** were represented by three clones each, **MFF** and **PHB2** by two clones, whereas all the rest were single clones. Interestingly, the autoreactive sequences of the nDNA-encoded mitochondrial genes were mapped to their protein-coding regions as well as to non-coding regions, specifically the 3'-UTRs. As indicated in Table 1, autoantibodies in BC sera significantly associated with invasive BC targeted protein-coding exonic regions of the **PKM2** (Figure 2B), **MAPK3** (Figure 3B), **COX7A2** (Figure 3A), and **TSPOAP1** (Figure 4B) genes, but only intronic regions of **SPATA5** (Figure 3C). For **GAPDH** (Figure 2A), **MFF** (Figure 4A), **PHB2** (Figure 4C), **COA4** (Figure 5A), and **MNRR1** (Figure 5C) genes, only 3'-UTR sequences were recognized as non-self, whereas for **GSTP1**

(Figure 2C) and **HAGH** (Figure 5B), the 3'-UTR as well as protein-coding exonic regions all displayed autoreactivity.


In Figures 2–7, if there is more than one RefSeq gene model per gene due to alternative initiation/splicing/termination and/or database redundancy, the selection of the model to use was based on visual assessment, in the UCSC Genome Browser, of the gene's underlying mRNAs and ESTs (not shown in these figures) in terms of the numbers of mRNAs and ESTs supporting each transcript model; where mRNA distribution was approximately equal between transcript isoforms, ESTs were used as tiebreakers. Direction of phages (arrow inside phage box) was determined based on the orientation of canonical splice site (GT-AG) and/or polyadenylation (AATAAA, ATATAA) sequences; if no such sequences were found direction was unknown and phage box is shown without directional arrows.



Long non-coding RNA and intergenic sequences represented by our library phages are targeted by autoantibodies in breast cancer

Of the 97 nDNA-encoded phage sequences significantly associated with the diagnosis of invasive BC by autoantigen microarray analyses, several clones mapped to the Long Intergenic Non-Protein Coding RNA 2381 (*LINC02381*), and to intergenic phages that may be parts of uncharacterized lncRNAs adjacent to the ERCC Excision Repair 4 (*ERCC4*), C-X-C Motif Chemokine Ligand 13 (*CXCL13*), SRY-Box Transcription Factor 3 (*SOX3*), Protocadherin 1 (*PCDH1*), Epididymal Protein 3B (*EDDM3B*), and Growth Factor Receptor Bound Protein 2 (*GRB2*) genes (Figures 6, 7;

Table 2; Supplementary Table S2). The clone representing the putative lncRNA adjacent to *ERCC4* represents the validation of an identical sequence identified using a different, independent collection of BC sera in 2011. That sequence was previously reported by us to GenBank (Phage 1008 = accession number JK649852) (Supplementary Table S2). At that time, little was known about lncRNAs (Kapranov et al., 2007; Spizzo et al., 2012), and the significance of this clone as a potential match of a new non-protein-coding transcript had been unclear to us. *LINC02381* and the intergenic-mapping phage sequences identified as neighbors of *ERCC4*, *CXCL13*, *SOX3*, *EDDM3B* and *PCDH1* were all identified by biopanning the multi-cell line cDNA library, whereas the intergenic-mapping phage sequences identified as neighbors of *GRB2* were cloned from the Novagen library.



Discussion

Mitochondrial autoreactivity plays a role in breast carcinogenesis

Multiple nDNA-encoded mitochondrial genes (Table 1) were identified during our immune-screening analysis of BC cDNA libraries. These genes have been linked to energy metabolism, cell proliferation, apoptosis, disease susceptibility, and ribosomal biogenesis (Kim et al., 2017; Abate et al., 2020). Autoreactivity to mitochondrial antigens is an indication of autoimmunity in BC (Fernández Madrid et al., 2004; Aras et al., 2019). The autoreactivity of nDNA-encoded mitochondrial gene products, reported in the present study, provides further evidence for mitochondrial autoimmunity in BC. Specifically, we identified autoreactive *GAPDH* and *PKM2* clones (multi-cell line cDNA

library) (Table 1; Supplementary Table S1); these genes play a key role in aerobic glycolysis and apoptosis, while *GAPDH* expression is also associated with BC cell proliferation and tumor aggressiveness (Guo et al., 2013). Further, we previously reported that antibody reactivity to centrosome assembly and/or microtubule proteins was highly associated with the diagnosis of BC (Maroun et al., 2017), suggesting that the autoreactivity might be the expression of autoimmunity developing in breast carcinogenesis. Autoreactivity of the 3'-UTR of *GAPDH* (Figure 2A) as well as of the coding and noncoding regions of *PKM2* (Figure 2B), a gene whose product catalyzes the last step of glycolysis and plays an important role in tumor cell proliferation, may indicate that their gene dysfunction promotes carcinogenesis. *PKM2* is also upregulated in BC tissue, and—consistent with our phage-based screening results—high levels of *PKM2* have been associated with poor prognosis of BC patients (Zhu et al., 2017).



FIGURE 5

COA4, *HAGH*, and *MNRR1* gene regions as autoreactive BC antigens identified by UCSC Genome Browser BLAT mapping and annotation of uniquely patient-sera-reactive phages. (A) Identified phage within 3'-UTR region of *COA4*. (B) Identified phage included protein coding region as well as 3'-UTR region of *HAGH*. (C) Identified phage included protein coding region as well as 3'-UTR region of *MNRR1*; UTR, untranslated region; kb, kilobase; *COA4*, cytochrome C oxidase assembly factor 4 homolog; *HAGH*, hydroxyacylglutathione hydrolase; *MNRR1*, mitochondrial nuclear retrograde regulator 1.

We also identified *MAPK3* as a BC autoantigen (Table 1; Supplementary Table S1). The MAP Kinase pathway is central in cancers, and is interesting in that the *PKM2* and tristetraprolin (TTP) interaction is crucial for the control of breast cancer cell proliferation (Huang et al., 2016). The p38/MAPK pathway might be involved in this regulatory mechanism since treatments with the p38 inhibitor SB203580 or p38 siRNA abolished TTP protein degradation induced by *PKM2* (Huang et al., 2016). Additionally, *PKM2* promotes stemness of breast cancer cells through the Wnt/ β -catenin pathway (Zhao et al., 2016). Collectively, several members of the

MAPK pathway and fundamental energy metabolism genes are autoantigenic in our screen, and are known from prior work to be directly pertinent to breast cancer carcinogenesis.

In addition, here we found that the protein-coding region and the 3'-UTR of the *GSTP1* gene were targeted by BC autoantibodies (Figure 2C; Table 1; Supplementary Table S1). The *GSTP1* is frequently inactivated in BC and other cancers (Lin and Nelson, 2003), whereas its polymorphisms have been associated with elevated BC risk (Sergentanis and Economopoulos, 2010). Likewise, it partially inhibits the c-Jun

TABLE 1 NDNA-encoded mitochondrial autoantigens associated with the diagnosis of invasive breast cancer.

Antigen	(p) BC	Accession	cDNA Library	Target
<i>GAPDH</i> ^a	0.001	NR_152,150.2	Multi-cell line	3' UTR
<i>PKM2</i> ^a	0.001	NM_001206799.2	Multi-cell line	Protein-coding region
<i>GSTP1</i> ^a	0.02	NM_000852.4	Multi-cell line	Protein-coding region, and 3'UTR
<i>COX7A2</i>	8.23E-09	NP_00153221.1	Multi-cell line	Protein-coding region
<i>MAPK3</i>	0.01	NM_001040056.3	Multi-cell line	Protein-coding region
<i>SPATA5</i> ^a	4.94E-06	NG_051570.1	Multi-cell line	Intron
<i>MFF</i> ^a	0.001	NR_102,266.2	Tumor tissue-derived (Novagen)	3' UTR
<i>TSPOAP1</i>	0.001	NM_024418.3	Tumor tissue-derived (Novagen)	Protein-coding region
<i>PHB2</i>	0.04	NM_001267700.1	Multi-cell line	3' UTR
<i>COA4</i>	0.001	NM_016565.3	Multi-cell line	3' UTR
<i>HAGH</i>	0.05	NM_005326.6	Multi-cell line	Protein-coding region, and 3' UTR
<i>MNRR1</i> ^b	6E-120	NM_016139.4	Multi-cell line	Protein-coding region and 3' UTR

^aGenes and *p* values were included as unpublished data in a review that appeared prior to this paper; however, the raw data was not published (Fernández Madrid et al., 2020).

^bAlready published by our group as autoreactive mitochondrial gene in BC (Aras et al., 2019).

GAPDH, glyceraldehyde 3-phosphate dehydrogenase; *PKM2*, pyruvate kinase isoenzyme M2; *GSTP1*, glutathione S-transferase Pi 1; *COX7A2*, cytochrome c oxidase subunit 7A2; *MAPK3*, mitogen activated protein kinase 3; *SPATA5*, spermatogenesis associated protein 5; *MFF*, mitochondrial fission factor; *TSPOAP1*, translocator protein, mitochondrial peripheral-type benzodiazepine receptor-associated protein; *PHB*, Prohibitin 2; *COA4*, Cytochrome C Oxidase Assembly Factor 4 Homolog; *HAGH*, Hydroxyacylglutathione Hydrolase. Exons contain protein-coding regions and 3'-UTRs (the last exon of a coding gene contains the end of its protein-coding sequence and all of its 3'-UTR).


N-terminal kinase (JNK)-mediated cell signaling pathway that is part of the MAPK family (Wang et al., 2001) (Morrison, 2012). Downstream of the JNK pathway are the P53 and nuclear factor kappa B (NF- κ B) pathways (Buschmann et al., 2000). JNK activation is a cellular response to environmental inflammatory stresses, hence the *GSTP1* being targeted by autoantibodies in BC is compatible with the hypothesis that autoimmune tissue damage in BC leads to chronic inflammation and tumorigenic signals (Fernández Madrid et al., 2015; Maroun et al., 2017; Aras et al., 2019) (Adler et al., 1999). Autoantibodies targeting *GSTP1* and the AP-1 complex suggest that the immune system detects the participation of these signal transduction molecules in breast carcinogenesis.

As additional evidence for the contribution of mitochondrial autoimmunity to breast carcinogenesis, autoantibodies in BC sera were found to target coding and noncoding regions of the *COX7A2* gene (Figure 3A) and 3'-UTR of *COA4* (Figure 5A; Table 1; Supplementary Table S1). *COX7A2* is a component of cytochrome *c* oxidase (COX), the last enzyme of the mitochondrial electron transport chain that drives oxidative phosphorylation and has a critical role in regulating energy production in mitochondria, a vital process for cell survival (Zhang et al., 2016). *COX7AR* (COX subunit VIIa polypeptide 2-like protein), a novel COX subunit recently found to be involved in mitochondrial supercomplex assembly and respiration, is expressed in high energy-demanding tissues (such as aggressive human BC), responds to estrogen (a nuclear hormone that is the key effector of estrogen-responsive ER-positive breast cancer, one of the three fundamental types of breast cancer), and resembles both *COX7A2* and *COX7A1* (Zhang et al., 2016). We found no

direct evidence of involvement of *COA4* in BC in the literature but given that it is involved in stabilizing the membrane association of cytochrome *c* (Gladych et al., 2021), we think that the presence of antibodies against its product may alter the function of COX. The autoreactivity of the mtDNA-encoded enzyme components of complexes I, IV, and V of the catalytic unit (Maroun et al., 2017), and that of *COX7A2* and *COA4*, suggest that the electron transport chain is deregulated in BC.

Our finding of BC-associated autoreactivity of the non-coding region of the *SPATA5* (Figure 3B; Table 1; Supplementary Table S1) suggests that this autoantibody may be a biomarker of BC risk as well as of *SPATA5* dysregulation. *SPATA5* is implicated in ribosome biogenesis (Tafforeau et al., 2013; Prattes et al., 2019), a crucial process for cell growth and proliferation that is often upregulated in cancer cells and plays a key role in the development and progression of most spontaneous cancers (Pelletier et al., 2018).

We also found that autoantibodies in BC sera targeted both coding and non-coding regions of the *TSPOAP1* gene (Figure 4B; Table 1; Supplementary Table S1). This gene encodes a highly conserved protein of the mammalian outer mitochondrial membrane, the peripheral-type benzodiazepine receptor-associated protein 1 (PBR), which was found to be present in aggressive breast cancer cell lines and in human glioma cells, where it may be involved in cell proliferation (Corsi et al., 2008). Its functions include mitochondrial regulation, steroid biosynthesis and import into mitochondria, mitochondrial oxidative phosphorylation, as well as contributions to cell differentiation, proliferation, and apoptosis (Corsi et al., 2008; Batarseh and Papadopoulos, 2010). Thus, the autoreactivity of



TSPOAPI in BC might reflect its role in apoptosis and cell proliferation.

BC autoantibodies also recognized as non-self the 3'-UTR of *MFF* (Figure 4A). Among pathways related to *MFF*, apoptosis and autophagy are both critical in breast carcinogenesis, (Gandre-Babbe and van der Bliek, 2008; Simula et al., 2017), and there is a connection between BC and mitochondrial fission abnormalities (Tang et al., 2018; Humphries et al., 2020). Here we found that the autoreactivity of *MFF* is localized to the 3'-UTR and does not involve the protein-coding region (Figure 4A; Table 1; Supplementary Table S1).

This suggests that the quality control mechanism responsible for mitochondrial fission may be impaired in breast carcinogenesis through dORF-dependent or direct RNA-dependent functions of the *MFF* mRNA.

The 3'-UTR of *PHB2* (Figure 4C) was also targeted by autoantibodies in BC, consistent with the gene's cancer-relevant roles in oxidative phosphorylation, mitochondrial biogenesis and apoptosis (Signorile et al., 2019). *PHB2* was also found to play a role as an estrogen receptor alpha repressor, which results in an overall negative effect on estrogen-dependent cancers like BC. However, *PHB2* can




FIGURE 7
 Diagrammatic representation of lincRNA *LINC02381* matching and intergenic sequences from uniquely BC-patient-sera-reactive phages mapping close to *PCDH1*, *EDDM3B*, and *GRB2*. (A) Phage 165, an intergenic phage, close to the *PCDH1* coding gene. (B) Phage 752, an intergenic phage, close to the *EDDM3B* coding gene. (C) Phage 33, an intergenic phage, close to the *GRB2* coding gene and *Y-RNA* gene. (D) A hit within the lincRNA *LINC02381*; *PCDH1*, Protocadherin 1; *EDDM3B*, Epididymal Protein 3B; *GRB2*, Growth Factor Receptor Bound Protein 2; UTR, untranslated region; kb, kilobase.

interact with brefeldin A-inhibited guanine nucleotide-exchange protein 3 (BIG3) in BC, which captures PHB2 in the cytoplasm of cancer cells and thereby inhibits the suppressive ability of PHB2 (Yoshimaru et al., 2013). In a similar way, we hypothesize that targeting *PHB2* by autoantibodies disrupts its role as tumor suppressor.

Furthermore, the autoantibodies reacted to protein-coding and 3'-UTR regions of *HAGH* (Figure 5B), part of a pathway to detoxify methylglyoxal (MGO). The role of MGO in cancer is controversial because lower doses of MGO are able to establish an adaptive response in cancer cells while higher doses cause cellular apoptosis (Leone et al., 2021). We think

TABLE 2 LncRNA antigens associated with the diagnosis of invasive breast cancer.

Antigen	(p) BC	Transcript model accession number	cDNA Library
<i>LINC02381</i>	0.0007	NR_026656.1	Multi-cell line
lncRNA neighbor of <i>CXCL13</i>	2.82e-26	None	Multi-cell line
lncRNA neighbor of <i>ERCC4</i>	0.0009	JK649852	Multi-cell line
lncRNA neighbor of <i>SOX3</i>	1.04e-08	None	Multi-cell line
lncRNA neighbor of <i>PCDH1</i>	4.89E-26	None	Multi-cell line
lncRNA neighbor of <i>EDDM3B</i>	5.65E-05	None	Multi-cell line
lncRNA neighbor of <i>GRB2</i>	7.00E-09	None	Tumor tissue-derived (Novagen)

LINC02381, long intergenic non-protein coding RNA, 2381; *CXCL13*, C-X-C motif chemokine ligand 13; *ERCC4*, ERCC, Excision Repair 4; *SOX3*, SRY-Box Transcription Factor 3, *PCDH1*, Protocadherin 1; *EDDM3B*, Epididymal Protein 3B; *GRB2*, Growth Factor Receptor Bound Protein 2.

the alteration of *HAGH* as a result of autoantibody targeting plays a role in influencing the role of MGO in BC. Finally, consistent with our data on *MNRR1* autoreactivity in breast carcinogenesis (Aras et al., 2019), we found that autoantibodies in BC sera targeted the 3'-UTR region of *MNRR1* (Figure 5C).

Protein-coding as well as non-coding regions of nuclear genomic DNA-encoded mitochondrial genes are targeted by autoantibodies in breast cancer

Little is known about the immunogenicity of nucleic acids in cancer and about the possibility that direct autoreactivity of RNA moieties, in addition to that of peptides encoded by the RNAs' ORFs, may deregulate the function of important gene products involved in carcinogenesis. Previous reports outlined that RNA molecules can form surfaces that mimic those of proteins and can trigger reactivity of autoantibodies with RNA surfaces due to cross-reactivity between a protein epitope and the RNA (Keene, 1996). Conformational RNA epitopes were discovered because autoantibodies in the sera of patients with systemic autoimmune diseases react directly with discrete structural elements in the U1 RNA of the small nuclear ribonucleoproteins (snRNPs), transfer RNA (tRNA) and ribosomal RNA (rRNA) (Deutscher and Keene, 1988; Uchiyama et al., 1991). More recent reports showed numerous autoreactive RNA sequences in the RADs in humans and in animal models of systemic lupus erythematosus (SLE), as well as in viral infections (Tan, 1982; Suurmond and Diamond, 2015). Although many types of RNA sequences are normally untranslated, they play an important role in regulating gene expression in multiple ways. For instance, introns contain numerous transcriptional regulatory elements, may encompass enhancers or alternative promoters, can regulate alternative splicing, affect the transcript stability or half-life, and/or modulate the efficiency of mRNA translation (Shaul, 2017). The 3'-UTR is involved in numerous regulatory processes

including transcript cleavage, translation, and mRNA subcellular localization (Navarro et al., 2021). In addition, in our previous work we have proven that some of these 3'-UTR regions sequences are translated in human cells and in BC (Bánfai et al., 2012; Choo et al., 2022).

Intronic autoreactivity, such as what we observed in *SPATA5* (Figure 3C), in theory may be a consequence of intron retention from aberrant or incomplete splicing, followed by translation of the intron-encoded continuation of the gene's ORF or a secondary intronic ORF. This process may yield a protein even though that protein is truncated and/or out-of-frame in reference to the mRNA's translation product. Deregulation of alternative splicing is thought to be important in aggressive BC (Yang et al., 2019). Splicing could also play a protective role against genetic instability in eukaryotic cells by preventing R-loop accumulation (Bonnet et al., 2017); this suggests a possible mechanism by which the autoantibodies targeting introns can influence carcinogenesis. As opposed to the role of uORFs in gene regulation, the role of dORFs is still unclear; recent reports suggested they may enhance translation of the canonical ORF and, depending on the number of dORFs in the gene, this effect varies (Wu et al., 2020). Our identification of immunoreactive sequences from the 3'-UTR regions of several genes (Figures 2, 6; Table 1) indicates that the autoantibodies target either the mRNA directly or the translated peptides of the dORFs, suggesting that dORF translation from these genes' mRNAs may be immunogenic in BC. Mutations in the 3'-UTR may mediate oncogene activation or tumor suppressor inactivation by altering microRNA (miRNA/miR)-binding efficiency to the miRs' specific cognate sites (Nicoloso et al., 2010). Frequent somatic mutations in the 3'-UTR of *GAPDH* have been reported to promote the growth of ovarian cancer by sponging miR-125 and thereby affecting the expression of Signal Transducer and Activator of Transcription 3 (STAT3) (Liu et al., 2020). Here we found that autoreactivity of the 3'-UTR of *GAPDH* (Figure 2A) is highly associated with the diagnosis of invasive BC (Table 1) and we speculate that, similarly to the findings in ovarian cancer (Liu et al., 2020), changes in the 3'-

UTR responsible for autoreactivity may disturb the binding of a miRNA to the 3'-UTR of the *GAPDH* mRNA. We also found that the 3'-UTR of *MFF* (Figure 4A) is targeted by autoantibodies in BC sera. It is possible that the expression of *MFF* in BC may be influenced by the binding of miRNAs to its 3'-UTR. MiR-376b-3p can attenuate mitochondrial fission and cardiac hypertrophy by targeting the 3'-UTR of *MFF* (Sun et al., 2018). Moreover, members of the miR-376 family have been implicated in breast and ovarian cancers, gliomas, and leukemia, and in the regulation of autophagy. This is potentially important because dysregulation of autophagy is a key feature of BC and other cancers (Zhang et al., 2018).

Our results point to direct immune autoreactivity of protein-coding gene 3'-UTRs and introns *in vitro*, without participation of immune cells or the direct influence of the microenvironment. This suggests that the autoimmunity drivers in BC may affect the epithelial cells in the breast early in carcinogenesis. Since immune-screening of the multi-cell line library used RNA from established BC cell lines for cDNA library construction, the recognition of the cloned gene products as non-self also suggests the possibility that cancer epithelial cells, in addition to being able to produce immunoglobulins, can hijack to some extent the process of antigen presentation. The autoreactivity of the mtDNA-encoded enzyme components of the ETC catalytic unit and that of *COX7A2* along with *COA4* suggests that, even though mitochondria often behave normally in assays, the transfer of electrons may be altered in BC. In addition, the large number of autoreactive mitochondrial gene products generated in cancer epithelial cells without participation of immune cells suggests inherent abnormalities of mitochondria in BC.

Non coding RNA dysregulation as a consequence of autoreactivity may play a role in breast carcinogenesis

Many tumor antigens are not detected by the immune system because they are not adequately presented by dendritic cells (Apavaloaei et al., 2020). The lncRNA, and the 3'-UTR and intronic regions that we report here were cloned from the multi-breast cancer cell line cDNA library made with RNA from BC cells devoid of signals from the tumor environment. We know that these antigens are recognized by the immune system since they trigger an autoantibody response. However, although epithelial cancer cells are poor antigen presenting cells of major histocompatibility complex (MHC)-associated peptides, our data indicate that cancer cells are involved in some way in the presentation of these lncRNAs to the immune system as indicated by the reacting autoantibodies. We don't know how cancer epithelial cells present these immunogenic RNA sequences to immunocompetent cells, and this question deserves further investigation.

Anti-nucleic acids autoantibodies are hallmarks of autoimmune rheumatic diseases: anti-DNA antibodies are characteristic of systemic lupus erythematosus (SLE) while anti-RNA autoantibodies commonly occur in SLE and Sjögren syndrome, as well as in viral diseases (Blanco et al., 1991; Yoshimi et al., 2012). Despite multiple reports of autoantibodies in cancer sera, to our knowledge autoantibodies targeting lncRNA have not been previously reported. Our finding is significant and novel because, although dysregulation of lncRNA associated with various diseases including breast cancer has been extensively reported (Suvanto et al., 2020), we found no reports of dysregulation of lncRNAs induced by immune autoreactivity. We also have identified multiple intergenic phages that are part of ncRNAs and we are unclear whether they would be part of previously unrecognized lncRNAs.

In this work, we identified *LINC02381* located ~50 kb away from Single-strand selective monofunctional uracil-DNA glycosylase (*SMUG1*) as a BC antigen highly associated with the diagnosis of BC (Table 2; Supplementary Table S2). *LINC02381* has attracted considerable attention for its strong links with the development of solid tumors including BC and autoimmune diseases. It is downregulated in gastric cancer (Jafarzadeh and Soltani, 2020) and is part of a signature of immune-related lncRNAs in BC (Ghafouri-Fard et al., 2021). *In vitro* studies indicated that *LINC02381* may function as a tumor suppressor by regulating the phosphatidylinositol 3-kinase (PI3K-AKT) signaling pathway (Jafarzadeh et al., 2020) and more recently this was confirmed *in vivo* where a knockdown of the gene was found to hinder proliferation, migration and invasion of BC cells, while overexpression promoted carcinogenesis (Huang et al., 2022). PIK3CA mutations, as well as AKT activation by phosphorylation (pAKT), are detected in many cancers, especially in BC (Yang et al., 2016). Thus, autoreactivity of *LINC02381* may be clinically significant by impairing its ability to regulate PI3K-AKT. As mentioned above, as a breast cancer autoantigen *LINC02381* inhibits gastric cancer progression by regulating Wnt signaling (Jafarzadeh and Soltani, 2020), a highly active pathway in cancer cells (Kazi et al., 2016). A further link between BC and rheumatic autoimmune diseases was suggested by the report that *LINC02381* can exacerbate rheumatoid arthritis through adsorbing miR-590-5p and activating the mitogen activated protein kinase signaling pathway (Wang and Zhao, 2020). For example, *LINC02381* has been shown to accelerate cancer progression in osteosarcoma, cervical cancer, and glioma (Chen et al., 2020; Bian et al., 2021; Sun et al., 2021), and to function as a tumor suppressor in breast and gastric cancers (Jafarzadeh and Soltani, 2020; Ghafouri-Fard et al., 2021). Since *LINC02381* exacerbates rheumatoid arthritis (Wang and Zhao, 2020), its discovery as a BC autoantigen provides another example of a lncRNA exerting effects at the interface of cancer and autoimmune diseases. The low expression of *SMUG1* was also associated with poor survival in ER positive BC and improved survival in ER- BC patients,

suggesting that it plays a variable role in BC and can be used to predict response to therapy (Abdel-Fatah et al., 2013).

In the present study, four phage clones mapped to an intergenic sequence, possibly representing a previously uncharacterized lncRNA neighbor of the *CXCL13* gene (located ~9.5 kb away from the 3' end of *CXCL13*) (Figure 6B), were targeted by autoantibodies in BC sera (Table 2; Supplementary Table S2). The inflammatory chemokine *CXCL13* is associated with the chronic inflammatory conditions severe rheumatoid arthritis (Bugatti et al., 2014) and multiple sclerosis (Krumbholz et al., 2006). The autoreactivity-induced deregulation of *CXCL13* in BC reported here supports existing work reporting on chronic inflammation and cancer development (Coussens and Werb, 2002; Mantovani et al., 2008). Additionally, it is known that *CXCL13* is overexpressed in BC (Panse et al., 2008) and associated with BC progression, poor prognosis and metastases (Biswas et al., 2014). One possible mechanism is that *CXCL13*-C-X-C Motif Chemokine Receptor 5 (*CXCR5*) co-expression may regulate epithelial to mesenchymal transition of BC cells during lymph node metastasis (Biswas et al., 2014). However, this chemokine has paradoxically been associated with improved outcome in patients with the luminal-human epidermal growth factor receptor 2 subtype (Razis et al., 2020), and in patients with HER-2 associated BC (Razis et al., 2012). Nonetheless, our analysis of the ENCODE Transcription Factor ChIP-Seq dataset in the UCSC Genome Browser revealed the *CXCL13*-neighbor phage sequence contains an experimentally-validated consensus binding site for the transcription factor FOXA1, a key mediator of hormonal response in breast cancer (Robinson and Carroll, 2012). The finding that an intergenic non-coding sequence near the *CXCL13* gene is highly associated with diagnosis of BC suggests that autoreactivity of this sequence regulates the adjacent *CXCL13* gene.

Autoantibodies in BC targeted four clones of a non-coding sequence (GenBank accession: JK649852, a phage from our earlier work) that map to an ultra-conserved non-coding region in UCSC Genome Browser's phyloP analysis of MultiZ 100-species genome alignments and is located ~370 kb upstream of the *ERCC4* gene (Figure 6A). The sequence also overlaps the intronic region of the lncRNA gene *U91319* (Table 2; Supplementary Table S2), although it does not belong to that lncRNA's transcriptional unit. This lncRNA is part of an immune-related lncRNA signature predicting survival of uterine corpus endometrial carcinoma patients (Sun et al., 2021), potentially suggesting a broad role for it in the disorders of the female reproductive system. In addition, *U91319* was hypermethylated in astrocytomas, the most common type of glioma (Bendahou et al., 2020). Interestingly, we have identified glioma mutation factor β (GMF- β) as an autoantigen associated with the diagnosis of BC ($p = 0.02$). GMF- β promotes glial differentiation. Neurogenesis and vasculogenesis

share common regulators with gliomagenesis, suggesting that GMF- β is important in glioma progression *via* promoting neovascularization (Kuang et al., 2015). The phage sequence targeted by BC autoantibodies maps near the *ERCC4* gene (Figure 6A), which is involved in Nucleotide Excision Repair (NER) pathway and has been associated with risk of BC in a 2-stage case-control study in Spanish and Finnish populations and that variation of the gene was associated with a protective effect (Milne et al., 2006). It is very interesting that NER is particularly targeted by autoantibodies in BC. We have reported that the Ku antigen, which plays a critical role in mammalian DNA double-strand breaks repair, is recognized by some patients with the scleroderma-polymyositis overlap syndrome (Mimori et al., 1990) and has been widely implicated in tumor biology, is a breast cancer autoantigen (Fernández Madrid et al., 2004). Other studies have implicated Ku as a key DNA damage repair protein in breast cancer (Alshareeda et al., 2013). We have also reported that the RPA32 subunit of replication protein A (RPA) is targeted by autoantibodies in BC (Tomkiel et al., 2002). The DNA-binding protein RPA plays a major role in DNA metabolism and is an essential component of NER. The data that we report here on the possible link between *ERCC4* and BC together with our previous findings of autoreactive Ku antigen and the central role of RPA in DNA replication, recombination, and repair suggest that autoimmunity to *ERCC4*, Ku, and RPA32 reflects molecular changes involved in the process of tumorigenesis, in particular on the importance of NER in breast carcinogenesis.

We also identified an intergenic phage located approximately 87 kb from the nearest coding gene, *SOX3* (Figure 6C; Table 2; Supplementary Table S2). Several studies reported the association of the SOX regulator family with BC (Mehta et al., 2019), and the progression of solid tumors and metastasis (Grimm et al., 2020). *SOX3p* is expressed in regulatory T cells (Tregs) and has a role in the control of autoimmunity and maintenance of transplantation tolerance (Rudensky, 2011). Our previous studies (Fernández Madrid et al., 2004; Maroun et al., 2017; Aras et al., 2019) indicate that specific mtDNA-encoded and nDNA-encoded mitochondrial gene products, nDNA-encoded signal transduction molecules, and lncRNAs are BC autoantigens. The finding of autoreactivity of intergenic phage neighbor to *SOX3* further supports the contention that autoimmunity-driven deregulation of multiple protein-coding and lncRNA genes is mechanistically involved in breast carcinogenesis. *SOX3* acts as a master regulator for regulatory Treg development and function and is indispensable for the maintenance of immunological self-tolerance and homeostasis (Rudensky, 2011; Morikawa and Sakaguchi, 2014).

An intergenic sequence located ~10 kb away from the 3' end of the *PCDH1* gene (Figure 7A; Table 2; Supplementary Table S2) was also identified as non-self. *PCDH1* has been studied in asthma patients and was upregulated during the development of airway epithelial barrier. This suggests that

PCDH1 may have a role in the physical barrier against environmental exposures (Kozu et al., 2015). *PCDH1* expression decreased in medulloblastoma, giving patients poor prognosis (Neben et al., 2004); we found no reports of an association with BC. As of now, there is no clearly identified mechanism of how this gene or its product could be associated with cancers. Disruption of this gene by autoreactivity, possibly through the lncRNA neighbor to *PCDH1*, may alter the response to environmental antigens that modulate tumor-immune interactions in BC.

Located ~2.7 kb upstream of *EDDM3B*, another intergenic-mapping phage sequence was identified as a BC autoantigen target (Figure 7B; Table 2; Supplementary Table S2). *EDDM3B* plays a role in the synthesis and secretion of epididymal epithelial cells proteins and male fertility (Damyanova et al., 2013). This gene is predictive of late metastasis in node negative BC (Schmidt et al., 2012). However, data about *EDDM3B* in BC are still lacking.

Another intergenic-mapping phage sequence ~7 kb upstream of *GRB2* was recognized as non-self (Figure 7C; Table 2; Supplementary Table S2). This gene is also close to other known non-coding RNA genes, including a *Y-RNA* gene (19 kb), *RNU6-938P* (3.6 kb) and *miR-3678* (7 kb) (Supplementary Material). The abnormal activation of *GRB2* by *HER2* (human epidermal growth factor receptor 2) signaling is strictly related to the development of BC (Daly et al., 1994; Ijaz et al., 2017). Circulating *Y-RNA* fragments with known cellular functions may participate in breast carcinogenesis and have potential as circulating biomarkers (Gulia et al., 2020) (Dhahbi et al., 2014).

Finally, the dysregulation of multiple lncRNAs (Prensner and Chinnaiyan, 2011; Hu et al., 2018), as well as genetic alterations in single nucleotide polymorphisms (SNPs) (Yan et al., 2015; Chandra Gupta and Nandan Tripathi, 2017; Miao et al., 2018) in cancer, collectively contribute to the global deregulation of the cancer genome, which has been described as “genome chaos” (Heng and Heng, 2020). Future studies should address the validation of our coding, lncRNA, and intergenic hits in additional patient cohorts as well as the elucidation of the potentially drug-targetable molecular mechanisms by which these autoreactive sequences may contribute to breast cancer pathogenesis.

Conclusion

Several nuclear DNA-encoded mitochondrial gene products recognized as autoantigens—*MNRR1*, *GAPDH*, *PKM2*, *GSTP1*, *COX7A2*, *MAPK3*, *SPATA5*, *TSPOAP1*, *MFF*, *PHB2*, *COA4*, and *HAGH*—in addition to their protein-coding regions, often feature their non-coding regions and 3'-UTRs detected in our phage-based screening. These genes are likely to be involved in breast carcinogenesis through direct immune autoreactivity and may be valuable biomarkers of aggressive BC. *GAPDH*, *PKM2*,

GSTP1, and *SPATA5*, as well as the lncRNA *LINC02381* and the intergenic phages neighbors of *ERCC4*, *CXCL13*, *SOX3*, and *EDDM3B* (all cloned by biopanning the multi-cell line library), were autoreactive in epithelial cancer cells *in vitro* suggesting the early participation of autoimmunity in breast carcinogenesis. Autoimmunity to *ERCC4* may underscore the pivotal involvement of nucleotide excision repair in breast carcinogenesis. The *SPATA5* gene's intronic autoreactivity may indicate BC risk, and its known participation in ribosome biogenesis may be an etiologic link to breast carcinogenesis. This work shows that, although autoreactivity of key mitochondrial gene products is involved in breast carcinogenesis, other non-mitochondrial pathways can also be oncogenic. It is important to note that these are results of an *in vitro* study and specific to our population in Detroit, and further *in vivo* studies would be necessary to confirm these findings. Many lncRNAs are deregulated in carcinogenesis (Suvanto et al., 2020) and have the potential to influence multiple oncogenic pathways but the reasons behind the deregulation of lncRNAs in cancer are poorly defined. Here we add autoreactivity as a potential cause that may explain part of the aberrant regulation of lncRNAs that is observed in carcinogenesis.

Data availability statement

The datasets presented in this study can be found in the GenBank database (<https://www.ncbi.nlm.nih.gov/genbank/>). The accession numbers can be found in the Supplementary Material. Further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving human participants were reviewed and approved by Ethics Committee of Henry Ford Healthcare System, IRB approval #10693 and Wayne State University (WSU) IRB; protocol #06030003557, Human Investigation Committee #038306A. The patients/participants provided their written informed consent to participate in this study.

Author contributions

FF was responsible for the conceptualization of the project and contributed to analysis and validation of the data, funding acquisition, methodology, supervision, and, together with DO, to writing the original draft and editing the manuscript. LL was responsible for the annotation of the cloned sequences, contributed to the validation of the data, and participated in reviewing and editing the manuscript. DO contributed to writing

the original draft and editing and reviewing the manuscript and participated in data curation and validation as well as to project administration. EK and EB participated in validation of data along and reviewing the manuscript. MM participated in methodology and data acquisition and analysis. LG contributed to the GO analysis and to editing and reviewing the manuscript; RA contributed to the GO analysis. AS was responsible for acquisition and classification of BC samples and for prospectively recruiting a non-cancer group of women with biopsy-proved absence of cancer as control. RG contributed to editing and reviewing the manuscript and participated in data validation.

Funding

This research was funded in part by NIH R01 CA 122277 to FF (PI), “Development and validation of a panel of breast cancer autoantigens for the early diagnosis of breast cancer,” and in part by the Flora Temple Fund, from Mrs. Mary Webber Parker through the Detroit Medical Center, by the NIH Director’s New Innovator Award 1DP2-CA196375 to LL (PI); by the Mohammed Bin Rashid University Internal Research Grant to LL and the Mohammed Bin Rashid University Postdoctoral Fellowship to RG and by the Al Jalila Foundation.

Acknowledgments

We thank Frederick Miller and Stephen Ethier for providing the BC established cell lines used to construct the multi-cell line BC cDNA library. We are grateful for the significant contributions of John Tomkiel, Robert Karvonen, Judith Abrams, Wei Chen, and Carol Peebles to the early stages of

this project. We apologize to a number of authors of pertinent work whom we could not cite in this paper because of space limitations.

Conflict of interest

Author LL has been collaborating with the Shenzhen Huayuan Biological Science Research Institute since 2019. This academic-industry research collaboration does not entail any past or present appointments at or compensation by the company, does not entail consulting, and is not remunerated. The research reported in this paper is completely outside the scope of this collaboration.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fgene.2022.970619/full#supplementary-material>

References

- Abate, M., Festa, A., Falco, M., Lombardi, A., Luce, A., Grimaldi, A., et al. (2020). “Mitochondria as playmakers of apoptosis, autophagy and senescence,” in *Seminars in cell & developmental biology* (Elsevier), 139–153.
- Abdel-Fatah, T. M. A., Albarakati, N., Howell, L., Agarwal, D., Moseley, P., Hawkes, C., et al. (2013). Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy. *Breast Cancer Res. Treat.* 142, 515–527. doi:10.1007/s10549-013-2769-6
- Adler, V., Yin, Z., Fuchs, S. Y., Benezra, M., Rosario, L., Tew, K. D., et al. (1999). Regulation of JNK signaling by GSTp. *EMBO J.* 18, 1321–1334. doi:10.1093/emboj/18.5.1321
- Alshareeda, A. T., Negm, O. H., Albarakati, N., Green, A. R., Nolan, C., Sultana, R., et al. (2013). Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer. *Breast Cancer Res. Treat.* 139, 301–310. doi:10.1007/s10549-013-2542-x
- Altschul, S. F., Boguski, M. S., Gish, W., and Wootton, J. C. (1994). Issues in searching molecular sequence databases. *Nat. Genet.* 6, 119–129. doi:10.1038/ng0294-119
- Apavaloai, A., Hardy, M. P., Thibault, P., and Perreault, C. (2020). The Origin and Immune Recognition of Tumor-Specific Antigens. *Cancers (Basel)* 12, 2607. doi:10.3390/cancers12092607
- Aras, S., Maroun, M.-C., Song, Y., Bandyopadhyay, S., Stark, A., Yang, Z.-Q., et al. (2019). Mitochondrial autoimmunity and MNRN1 in breast carcinogenesis. *BMC cancer* 19, 411–412. doi:10.1186/s12885-019-5575-7
- Bánfai, B., Jia, H., Khatun, J., Wood, E., Risk, B., Gundling, W. E., Jr., et al. (2012). Long noncoding RNAs are rarely translated in two human cell lines. *Genome Res.* 22, 1646–1657. doi:10.1101/gr.134767.111
- Barbosa, C., Peixeiro, I., and Romão, L. (2013). Gene expression regulation by upstream open reading frames and human disease. *PLoS Genet.* 9, e1003529. doi:10.1371/journal.pgen.1003529
- Batarseh, A., and Papadopoulos, V. (2010). Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states. *Mol. Cell. Endocrinol.* 327, 1–12. doi:10.1016/j.mce.2010.06.013
- Bendahou, M., Ibrahim, A., and Boutarouch, M. (2020). Identification of potential biomarkers for low-grade gliomas by analyzing the Genomics profiles and CpG Island methylator Phenotype of Patients in the TCGA Database. *Int. J. Appl. Biol. Pharm. Technol.* 11, 188–199.
- Bian, X., Sun, Y.-M., Wang, L.-M., and Shang, Y.-L. (2021). ELK1-induced upregulation lncRNA LINC02381 accelerates the osteosarcoma tumorigenesis

- through targeting CDCA4 via sponging miR-503-5p. *Biochem. Biophys. Res. Commun.* 548, 112–119. doi:10.1016/j.bbrc.2021.02.072
- Biswas, S., Sengupta, S., Roy Chowdhury, S., Jana, S., Mandal, G., Mandal, P. K., et al. (2014). CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis. *Breast Cancer Res. Treat.* 143, 265–276. doi:10.1007/s10549-013-2811-8
- Blanco, F., Kalsi, J., and Isenberg, D. A. (1991). Analysis of antibodies to RNA in patients with systemic lupus erythematosus and other autoimmune rheumatic diseases. *Clin. Exp. Immunol.* 86, 66–70. doi:10.1111/j.1365-2249.1991.tb05775.x
- Bonnet, A., Grosso, A. R., Elkaoutari, A., Coleno, E., Presle, A., Sridhara, S. C., et al. (2017). Introns protect eukaryotic genomes from transcription-associated genetic instability. *Mol. Cell* 67, 608–621. e606. doi:10.1016/j.molcel.2017.07.002
- Bugatti, S., Manzo, A., Vitolo, B., Benaglio, F., Binda, E., Scarabelli, M., et al. (2014). High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. *Rheumatol. Oxf.* 53, 1886–1895. doi:10.1093/rheumatology/keu163
- Buschmann, T., Yin, Z., Bhoomik, A., and Ronai, Z. (2000). Amino-terminal-derived JNK fragment alters expression and activity of c-Jun, ATF2, and p53 and increases H2O2-induced cell death. *J. Biol. Chem.* 275, 16590–16596. doi:10.1074/jbc.M910045199
- Chandra Gupta, S., and Nandan Tripathi, Y. (2017). Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets. *Int. J. Cancer* 140, 1955–1967. doi:10.1002/ijc.30546
- Chen, X., Zhang, Z., Ma, Y., Su, H., Xie, P., and Ran, J. (2020). LINC02381 promoted cell viability and migration via targeting miR-133b in cervical cancer cells. *Cancer Manag. Res.* 12, 3971–3979. doi:10.2147/CMAR.S23285
- Choo, S. W., Zhong, Y., Sandler, E., Goustin, A. S., Cai, J., Ju, D., et al. (2022). Estrogen distinctly regulates transcription and translation of lncRNAs and pseudogenes in breast cancer cells. *Genomics* 114, 110421. doi:10.1016/j.ygeno.2022.110421
- Corsi, L., Geminiani, E., and Baraldi, M. (2008). Peripheral benzodiazepine receptor (PBR) new insight in cell proliferation and cell differentiation review. *Curr. Clin. Pharmacol.* 3, 38–45. doi:10.2174/15748840878329878
- Coussens, L. M., and Werb, Z. (2002). Inflammation and cancer. *Nature* 420, 860–867. doi:10.1038/nature01322
- Cui, M., Huang, J., Zhang, S., Liu, Q., Liao, Q., and Qiu, X. (2021). Immunoglobulin expression in cancer cells and its critical roles in tumorigenesis. *Front. Immunol.* 12, 613530. doi:10.3389/fimmu.2021.613530
- Daly, R. J., Binder, M. D., and Sutherland, R. L. (1994). Overexpression of the Grb2 gene in human breast cancer cell lines. *Oncogene* 9, 2723–2727.
- Damyanova, V., Dimitrova-Dikanarova, D., Hadjidekova, S., Savov, A., Nesheva, D., Rukova, B., et al. (2013). Genomic study in patients with idiopathic azoospermia and oligoasthenoteratozoospermia. *Akush. Ginekol.* 52, 27–34.
- Deutscher, S. L., and Keene, J. D. (1988). A sequence-specific conformational epitope on U1 RNA is recognized by a unique autoantibody. *Proc. Natl. Acad. Sci. U. S. A.* 85, 3299–3303. doi:10.1073/pnas.85.10.3299
- Dhabhi, J. M., Spindler, S. R., Atamna, H., Boffelli, D., and Martin, D. I. (2014). Deep sequencing of serum small RNAs identifies patterns of 5' tRNA half and YRNA fragment expression associated with breast cancer. *Biomark. Cancer* 6, 37–47. doi:10.4137/BIC.S20764
- Dragomir, M. P., Manyam, G. C., Ott, L. F., Berland, L., Knutsen, E., Ivan, C., et al. (2020). FuncPEP: A database of functional peptides encoded by non-coding RNAs. *Noncoding. RNA* 6, 41. doi:10.3390/ncrna6040041
- Fernández Madrid, F., Grossman, L. I., and Aras, S. (2020). Mitochondria autoimmunity and MNRR1 in breast carcinogenesis: A review. *J. Cancer Immunol.* 2, 138–158. doi:10.3396/cancerimmunol.2.027
- Fernández Madrid, F., Maroun, M.-C., Olivero, O. A., Long, M., Stark, A., Grossman, L. I., et al. (2015). Autoantibodies in breast cancer sera are not epiphenomena and may participate in carcinogenesis. *BMC cancer* 15, 407–415. doi:10.1186/s12885-015-1385-8
- Fernández Madrid, F., Tang, N., Alansari, H., Granda, J. L., Tait, L., Amirikia, K. C., et al. (2004). Autoantibodies to annexin XI-A and other autoantigens in the diagnosis of breast cancer. *Cancer Res.* 64, 5089–5096. doi:10.1158/0008-5472.CAN-03-0932
- Fritzer, M., and Manns, M. (2002). Anti-mitochondrial antibodies. *Clin. Appl. Immunol. Rev.* 3, 87–113.
- Gandre-Babbe, S., and Van Der Blik, A. M. (2008). The novel tail-anchored membrane protein Mff controls mitochondrial and peroxisomal fission in mammalian cells. *Mol. Biol. Cell* 19, 2402–2412. doi:10.1091/mbc.e07-12-1287
- Gershwin, M. E., Mackay, I. R., Sturgess, A., and Coppel, R. L. (1987). Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. *J. Immunol.* 138, 3525–3531.
- Ghafouri-Fard, S., Asadi, M., Sohrabi, B., Arsang-Jang, S., Mehravaran, E., Taheri, M., et al. (2021). Down-regulation of a panel of immune-related lncRNAs in breast cancer. *Pathol. Res. Pract.* 224, 153534. doi:10.1016/j.prp.2021.153534
- Gladyck, S., Aras, S., Hüttemann, M., and Grossman, L. I. (2021). Regulation of COX assembly and function by twin CX(9)C proteins-implications for human disease. *Cells* 10, 197. doi:10.3390/cells10020197
- Grimm, D., Bauer, J., Wise, P., Krüger, M., Simonsen, U., Wehland, M., et al. (2020). The role of SOX family members in solid tumours and metastasis. *Semin. Cancer Biol.* 67, 122–153. doi:10.1016/j.semcancer.2019.03.004
- Gulia, C., Signore, F., Gaffi, M., Gigli, S., Votino, R., Nucciotti, R., et al. (2020). Y RNA: An Overview of Their Role as Potential Biomarkers and Molecular Targets in Human Cancers, 12. *Cancers (Basel)*
- Guo, C., Liu, S., and Sun, M. Z. (2013). Novel insight into the role of GAPDH playing in tumor. *Clin. Transl. Oncol.* 15, 167–172. doi:10.1007/s12094-012-0924-x
- Heng, J., and Heng, H. H. (2020). Genome chaos: Creating new genomic information essential for cancer macroevolution. *Semin. Cancer Biol.* 81, 160–175. doi:10.1016/j.semcancer.2020.11.003
- Hu, X. Y., Hou, P. F., Li, T. T., Quan, H. Y., Li, M. L., Lin, T., et al. (2018). The roles of Wnt/ β -catenin signaling pathway related lncRNAs in cancer. *Int. J. Biol. Sci.* 14, 2003–2011. doi:10.7150/ijbs.27977
- Huang, L., Yu, Z., Zhang, Z., Ma, W., Song, S., and Huang, G. (2016). Interaction with pyruvate kinase M2 destabilizes tristetraprolin by proteasome degradation and regulates cell proliferation in breast cancer. *Sci. Rep.* 6, 22449. doi:10.1038/srep22449
- Huang, S., Huang, P., Wu, H., Wang, S., and Liu, G. (2022). LINC02381 aggravates breast cancer through the miR-1271-5p/FN1 axis to activate PI3K/AKT pathway. *Mol. Carcinog.* 61, 346–358. doi:10.1002/mc.23375
- Humphries, B. A., Cutter, A. C., Buschhaus, J. M., Chen, Y.-C., Qyli, T., Palagama, D. S., et al. (2020). Enhanced mitochondrial fission suppresses signaling and metastasis in triple-negative breast cancer. *Breast Cancer Res.* 22, 60–18. doi:10.1186/s13058-020-01301-x
- Ijaz, M., Shahabz, M., Jiang, W., Fathy, A., Nesa, E., Wang, D., et al. (2017). Oncogenic role of Grb2 in breast cancer and Grb2 antagonists as therapeutic drugs. *Cancer Ther. Oncol. Int. J.* 3, 1–7. doi:10.19080/ctoj.2017.03.555618
- Jafarzadeh, M., and Soltani, B. M. (2020). Long noncoding RNA LOC400043 (LINC02381) inhibits gastric cancer progression through regulating Wnt signaling pathway. *Front. Oncol.* 10, 562253. doi:10.3389/fonc.2020.562253
- Jafarzadeh, M., Soltani, B. M., Soleimani, M., and Hosseinkhani, S. (2020). Epigenetically silenced LINC02381 functions as a tumor suppressor by regulating PI3K-Akt signaling pathway. *Biochimie* 171–172, 63–71. doi:10.1016/j.biochi.2020.02.009
- Kapranov, P., Cheng, J., Dike, S., Nix, D. A., Duttagupta, R., Willingham, A. T., et al. (2007). RNA maps reveal new RNA classes and a possible function for pervasive transcription. *Science* 316, 1484–1488. doi:10.1126/science.1138341
- Katayama, S., Tomaru, Y., Kasukawa, T., Waki, K., Nakanishi, M., Nakamura, M., et al. (2005). Antisense transcription in the mammalian transcriptome. *Science* 309, 1564–1566. doi:10.1126/science.1112009
- Kazi, M., Trivedi, T., Kobawala, T., and Ghosh, N. (2016). The potential of Wnt signaling pathway in cancer: A focus on breast cancer. *Cancer Transl. Med.* 2, 55–60. doi:10.4103/2395-3977.181437
- Keene, J. D. (1996). RNA surfaces as functional mimetics of proteins. *Chem. Biol.* 3, 505–513. doi:10.1016/s1074-5521(96)90139-8
- Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., et al. (2002). The human genome browser at UCSC. *Genome Res.* 12, 996–1006. doi:10.1101/gr.229102
- Kim, H.-J., Maiti, P., and Barrientos, A. (2017). “Mitochondrial ribosomes in cancer,” in *Seminars in cancer biology* (Elsevier), 67–81.
- Kozu, Y., Gon, Y., Maruoka, S., Kazumichi, K., Sekiyama, A., Kishi, H., et al. (2015). Protocadherin-1 is a glucocorticoid-responsive critical regulator of airway epithelial barrier function. *BMC Pulm. Med.* 15, 80. doi:10.1186/s12890-015-0078-z
- Krumbholz, M., Theil, D., Cepok, S., Hemmer, B., Kivisäkk, P., Ransohoff, R. M., et al. (2006). Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation

- is differentially linked to CNS immune cell recruitment. *Brain* 129, 200–211. doi:10.1093/brain/awh680
- Kuang, X.-Y., Jiang, X.-F., Chen, C., Su, X.-R., Shi, Y., Wu, J.-R., et al. (2015). Expressions of glia maturation factor- β by tumor cells and endothelia correlate with neovascularization and poor prognosis in human glioma. *Oncotarget* 7, 85750–85763. doi:10.18632/oncotarget.5509
- Kung, J. T., Colognori, D., and Lee, J. T. (2013). Long noncoding RNAs: Past, present, and future. *Genetics* 193, 651–669. doi:10.1534/genetics.112.146704
- Leone, A., Nigro, C., Nicolò, A., Prevezano, I., Formisano, P., Beguinot, F., et al. (2021). The dual-role of methylglyoxal in tumor progression – novel therapeutic approaches. *Front. Oncol.* 11, 645686. doi:10.3389/fonc.2021.645686
- Lin, X., and Nelson, W. G. (2003). Methyl-CpG-binding domain protein-2 mediates transcriptional repression associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells. *Cancer Res.* 63, 498–504.
- Liu, P., Zhong, Y., Cao, T., Sheng, X., and Huang, H. (2020). A frequent somatic mutation in the 3'UTR of GAPDH facilitates the development of ovarian cancer by creating a miR-125b binding site. *Oncol. Rep.* 44, 887–896. doi:10.3892/or.2020.7663
- Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008). Cancer-related inflammation. *Nature* 454, 436–444. doi:10.1038/nature07205
- Marchenko, S., Chernyavsky, A. I., Arredondo, J., Gindi, V., and Grando, S. A. (2010). Antimitochondrial autoantibodies in pemphigus vulgaris: A missing link in disease pathophysiology. *J. Biol. Chem.* 285, 3695–3704. doi:10.1074/jbc.M109.081570
- Maroun, M., Grossman, L., Lancaster, W., Long, M., Arshad, R., Aboukasm, G., et al. (2017). Mitochondrial encoded targets of breast cancer anti-mitochondrial antibodies implications of mitochondrial autoimmunity for breast cancer progression. *Sci. J. Molec Biomarkers Diag* 1, 001–008.
- Mehta, G. A., Khanna, P., and Gatz, M. L. (2019). Emerging role of SOX proteins in breast cancer development and maintenance. *J. Mammary Gland. Biol. Neoplasia* 24, 213–230. doi:10.1007/s10911-019-09430-6
- Miao, Y. R., Liu, W., Zhang, Q., and Guo, A. Y. (2018). lncRNAsNP2: an updated database of functional SNPs and mutations in human and mouse lncRNAs. *Nucleic Acids Res.* 46, D276–d280. doi:10.1093/nar/gkx1004
- Miller, B. E., Miller, F. R., Wilburn, D., and Heppner, G. H. (1988). Dominance of a tumor subpopulation line in mixed heterogeneous mouse mammary tumors. *Cancer Res.* 48, 5747–5753.
- Milne, R. L., Ribas, G., González-Neira, A., Fagerholm, R., Salas, A., González-Neira, E., et al. (2006). ERCC4 associated with breast cancer risk: A two-stage case-control study using high-throughput genotyping. *Cancer Res.* 66, 9420–9427. doi:10.1158/0008-5472.CAN-06-1418
- Mimori, T., Ohosone, Y., Hama, N., Suwa, A., Akizuki, M., Homma, M., et al. (1990). Isolation and characterization of cDNA encoding the 80-kDa subunit protein of the human autoantigen Ku (p70/p80) recognized by autoantibodies from patients with scleroderma-polymyositis overlap syndrome. *Proc. Natl. Acad. Sci. U. S. A.* 87, 1777–1781. doi:10.1073/pnas.87.5.1777
- Morikawa, H., and Sakaguchi, S. (2014). Genetic and epigenetic basis of Treg cell development and function: From a FoxP3-centered view to an epigenome-defined view of natural Treg cells. *Immunol. Rev.* 259, 192–205. doi:10.1111/imr.12174
- Morrison, D. K. (2012). MAP kinase pathways. *Cold Spring Harb. Perspect. Biol.* 4, a011254. doi:10.1101/cshperspect.a011254
- Navarro, E., Mallén, A., and Hueso, M. (2021). Dynamic variations of 3' UTR length reprogram the mRNA regulatory landscape. *Biomedicines* 9, 1560. doi:10.3390/biomedicines9111560
- Neben, K., Korshunov, A., Benner, A., Wrobel, G., Hahn, M., Kokocinski, F., et al. (2004). Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. *Cancer Res.* 64, 3103–3111. doi:10.1158/0008-5472.can-03-3968
- Nicoloso, M. S., Sun, H., Spizzo, R., Kim, H., Wickramasinghe, P., Shimizu, M., et al. (2010). Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. *Cancer Res.* 70, 2789–2798. doi:10.1158/0008-5472.CAN-09-3541
- Panse, J., Friedrichs, K., Marx, A., Hildebrandt, Y., Luetkens, T., Barrels, K., et al. (2008). Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. *Br. J. Cancer* 99, 930–938. doi:10.1038/sj.bjc.6604621
- Pelletier, J., Thomas, G., and Volarević, S. (2018). Ribosome biogenesis in cancer: New players and therapeutic avenues. *Nat. Rev. Cancer* 18, 51–63. doi:10.1038/nrc.2017.104
- Prattes, M., Lo, Y. H., Bergler, H., and Stanley, R. E. (2019). Shaping the nascent ribosome: AAA-ATPases in eukaryotic ribosome biogenesis. *Biomolecules* 9, E715. doi:10.3390/biom9110715
- Prensner, J. R., and Chinnaiyan, A. M. (2011). The emergence of lncRNAs in cancer biology. *Cancer Discov.* 1, 391–407. doi:10.1158/2159-8290.CD-11-0209
- Razis, E., Kalogeras, K. T., Kotoula, V., Eleftheraki, A. G., Nikitas, N., Kronenwett, R., et al. (2012). Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. *Clin. Breast Cancer* 12, 183–193. doi:10.1016/j.clbc.2012.03.006
- Razis, E., Kalogeras, K. T., Kotsantis, I., Koliou, G. A., Manousou, K., Wirtz, R., et al. (2020). The role of CXCL13 and CXCL9 in early breast cancer. *Clin. Breast Cancer* 20, e36–e53. doi:10.1016/j.clbc.2019.08.008
- Robinson, J. L., and Carroll, J. S. (2012). FoxA1 is a key mediator of hormonal response in breast and prostate cancer. *Front. Endocrinol.* 3, 68. doi:10.3389/fendo.2012.00068
- Rudensky, A. Y. (2011). Regulatory T cells and Foxp3. *Immunol. Rev.* 241, 260–268. doi:10.1111/j.1600-065X.2011.01018.x
- Schmidt, M., Hellwig, B., Gehrman, M., Koelbl, H., Boehm, D., Cadenas, C., et al. (2012). Prediction of late metastasis in node-negative breast cancer. *J. Clin. Oncol.* 30, 10551. doi:10.1200/jco.2012.30.15_suppl.10551
- Sergentanis, T. N., and Economopoulos, K. P. (2010). GSTT1 and GSTP1 polymorphisms and breast cancer risk: A meta-analysis. *Breast Cancer Res. Treat.* 121, 195–202. doi:10.1007/s10549-009-0520-0
- Shaul, O. (2017). How introns enhance gene expression. *Int. J. Biochem. Cell Biol.* 91, 145–155. doi:10.1016/j.biocel.2017.06.016
- Signorile, A., Sgaramella, G., Bellomo, F., and De Rasmio, D. (2019). Prohibitins: A critical role in mitochondrial functions and implication in diseases. *Cells* 8, E71. doi:10.3390/cells8010071
- Simula, L., Nazio, F., and Campello, S. (2017). The mitochondrial dynamics in cancer and immune-surveillance. *Semin. Cancer Biol.* 47, 29–42. doi:10.1016/j.semcancer.2017.06.007
- Spizzo, R., Almeida, M. I., Colombatti, A., and Calin, G. A. (2012). Long non-coding RNAs and cancer: A new frontier of translational research? *Oncogene* 31, 4577–4587. doi:10.1038/onc.2011.621
- Sun, X.-X., Wen, H.-Q., Zhan, B.-X., and Yang, P. (2021a). Identification of an immune-related lncRNA prognostic signature in uterine corpus endometrial carcinoma patients. *Clin. Lab.* 67. doi:10.7754/Clin.Lab.2021.210401
- Sun, Y. L., Li, S. H., Yang, L., and Wang, Y. (2018). miR-376b-3p attenuates mitochondrial fission and cardiac hypertrophy by targeting mitochondrial fission factor. *Clin. Exp. Pharmacol. Physiol.* 45, 779–787. doi:10.1111/1440-1681.12938
- Sun, Y., Wang, X., and Bu, X. (2021b). LINC02381 contributes to cell proliferation and hinders cell apoptosis in glioma by transcriptionally enhancing CBX5. *Brain Res. Bull.* 176, 121–129. doi:10.1016/j.brainresbull.2021.07.009
- Sunaga, N., Kohno, T., Kolligs, F. T., Fearon, E. R., Saito, R., and Yokota, J. (2001). Constitutive activation of the Wnt signaling pathway by CTNNB1 (β -catenin) mutations in a subset of human lung adenocarcinoma. *Genes Chromosom. Cancer* 30, 316–321. doi:10.1002/1098-2264(2000)9999:9999<::aid-gcc1097>3.0.co;2-9
- Suurmond, J., and Diamond, B. (2015). Autoantibodies in systemic autoimmune diseases: Specificity and pathogenicity. *J. Clin. Invest.* 125, 2194–2202. doi:10.1172/JCI78084
- Suvanto, M., Beesley, J., Blomqvist, C., Chenevix-Trench, G., Khan, S., and Nevanlinna, H. (2020). SNPs in lncRNA regions and breast cancer risk. *Front. Genet.* 11, 550. doi:10.3389/fgene.2020.00550
- Tafforeau, L., Zorbas, C., Langhendries, J. L., Mullineux, S. T., Stamatopoulou, V., Mullier, R., et al. (2013). The complexity of human ribosome biogenesis revealed by systematic nucleolar screening of Pre-rRNA processing factors. *Mol. Cell* 51, 539–551. doi:10.1016/j.molcel.2013.08.011
- Tan, E. M. (1982). Autoantibodies to nuclear antigens (ANA): Their immunobiology and medicine. *Adv. Immunol.* 33, 167–240. doi:10.1016/s0065-2776(08)60836-6
- Tang, Q., Liu, W., Zhang, Q., Huang, J., Hu, C., Liu, Y., et al. (2018). Dynamin-related protein 1-mediated mitochondrial fission contributes to IR-783-induced apoptosis in human breast cancer cells. *J. Cell. Mol. Med.* 22, 4474–4485. doi:10.1111/jcmm.13749
- Tomkiel, J. E., Alansari, H., Tang, N., Virgin, J. B., Yang, X., Vandevord, P., et al. (2002). Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer. *Clin. Cancer Res.* 8, 752–758.

- Uchiumi, T., Traut, R. R., Elkon, K., and Kominami, R. (1991). A human autoantibody specific for a unique conserved region of 28 S ribosomal RNA inhibits the interaction of elongation factors 1 alpha and 2 with ribosomes. *J. Biol. Chem.* 266, 2054–2062. doi:10.1016/s0021-9258(18)52208-0
- Wang, J., and Zhao, Q. (2020). Linc02381 exacerbates rheumatoid arthritis through adsorbing miR-590-5p and activating the mitogen-activated protein kinase signaling pathway in rheumatoid arthritis-fibroblast-like synoviocytes. *Cell Transpl.* 29, 963689720938023. doi:10.1177/0963689720938023
- Wang, T., Arifoglu, P., Ronai, Z., and Tew, K. D. (2001). Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. *J. Biol. Chem.* 276, 20999–21003. doi:10.1074/jbc.M101355200
- Wu, Q., Wright, M., Gogol, M. M., Bradford, W. D., Zhang, N., and Bazzini, A. A. (2020). Translation of small downstream ORFs enhances translation of canonical main open reading frames. *Embo J.* 39, e104763. doi:10.15252/embj.2020104763
- Yan, X., Hu, Z., Feng, Y., Hu, X., Yuan, J., Zhao, S. D., et al. (2015). Comprehensive genomic characterization of long non-coding RNAs across human cancers. *Cancer Cell* 28, 529–540. doi:10.1016/j.ccell.2015.09.006
- Yang, Q., Zhao, J., Zhang, W., Chen, D., and Wang, Y. (2019). Aberrant alternative splicing in breast cancer. *J. Mol. Cell Biol.* 11, 920–929. doi:10.1093/jmcb/mjz033
- Yang, S. X., Polley, E., and Lipkowitz, S. (2016). New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. *Cancer Treat. Rev.* 45, 87–96. doi:10.1016/j.ctrv.2016.03.004
- Yoshimaru, T., Komatsu, M., Matsuo, T., Chen, Y.-A., Murakami, Y., Mizuguchi, K., et al. (2013). Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells. *Nat. Commun.* 4, 2443. doi:10.1038/ncomms3443
- Yoshimi, R., Ueda, A., Ozato, K., and Ishigatsubo, Y. (2012). Clinical and pathological roles of ro/SSA autoantibody system. *Clin. Dev. Immunol.* 2012, 606195. doi:10.1155/2012/606195
- Zhang, K., Wang, G., Zhang, X., Hüttemann, P. P., Qiu, Y., Liu, J., et al. (2016). COX7AR is a stress-inducible mitochondrial COX subunit that promotes breast cancer malignancy. *Sci. Rep.* 6, 31742. doi:10.1038/srep31742
- Zhang, L., Chen, Y., Wang, H., Zheng, X., Li, C., and Han, Z. (2018). miR-376a inhibits breast cancer cell progression by targeting neuropilin-1 NR. *Oncotargets. Ther.* 11, 5293–5302. doi:10.2147/OTT.S173416
- Zhao, Z., Song, Z., Liao, Z., Liu, Z., Sun, H., Lei, B., et al. (2016). PKM2 promotes stemness of breast cancer cell by through Wnt/ β -catenin pathway. *Tumour Biol.* 37, 4223–4234. doi:10.1007/s13277-015-4121-8
- Zhu, H., Luo, H., Zhu, X., Hu, X., Zheng, L., and Zhu, X. (2017). Pyruvate kinase M2 (PKM2) expression correlates with prognosis in solid cancers: A meta-analysis. *Oncotarget* 8, 1628–1640. doi:10.18632/oncotarget.13703

Glossary

BC Breast Cancer

nDNA nuclear genomic DNA

GAPDH glyceraldehyde 3-phosphate dehydrogenase

PKM2 pyruvate kinase isoenzyme M2

GSTP1 glutathione S-transferase Pi 1

SPATA5 spermatogenesis associated protein 5

MFF mitochondrial fission factor

TSPOAP1 translocator protein

PBR peripheral-type benzodiazepine receptor-associated protein

UTR untranslated region

IFA Immunofluorescence

BBD Benign breast disease

RAD rheumatic autoimmune disease

AMA anti-mitochondrial antibody

PBC Primary biliary cholangitis

PV Pemphigus vulgaris

ETC electron transport chain

MNRR1 mitochondrial nuclear retrograde regulator 1

ncRNA non-coding RNA

ORF open reading frame

uORF upstream open reading frame

dORF downstream open reading frame

smORF small open reading frame

cDNA complementary DNA

IDC infiltrating ductal carcinoma

HFHs Henry Ford Health System

TAA Tumor Associated Antigen

PCR Polymerase Chain Reaction

BLAST Basic Local Alignment Search Tool

BLAT BLAST-like alignment tool

GO Gene ontology

mtDNA mitochondrial DNA

COX7A2 cytochrome c oxidase subunit 7A2

MAPK3 mitogen activated protein kinase 3

miRNA MicroRNA

STAT3 Signal Transducer And Activator of Transcription 3

TTP Tristetraprolin

AP-1 Activator Protein-1

JNK c-Jun N-terminal kinase

MAPK mitogen activated stress kinase family

PHB2 Prohibitin 2

COA4 Cytochrome C Oxidase Assembly Factor 4 Homolog

HAGH Hydroxyacylglutathione Hydrolase

MGO methylglyoxal

lncRNA long non-coding RNA

SNP single nucleated peptide

LINC02381 Long intergenic non-protein coding RNA 2381

CXCL13 C-X-C motif chemokine ligand 13

CCR4-NOT Carbon Catabolite Repression—Negative On TATA-less

PI3K-AKT Phosphatidylinositol 3-kinase

mTOR mammalian target of rapamycin

CDCA4 Cell Division Cycle Associated 4

CBX5 Chromobox 5

CXCR5 C-X-C Motif Chemokine Receptor 5

TFH T-Follicular helper cell

SOX3 SRY-Box Transcription Factor 3

PCDH1 Protocadherin 1

EDDM3B Epididymal Protein 3B

GRB2 Growth Factor Receptor Bound Protein 2

CTLA-4 Cytotoxic T-Lymphocyte Associated Protein 4

CTNNBIP 1 Catenin Beta 1